3.500NOK+11.64%Mkt Cap: 1.14B NOKP/E: —Last update: 2026-06-01
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.14B NOK
Enterprise Value1.24B NOK
Revenue (TTM)556.00K NOK
Gross Profit556.00K NOK
Net Income (TTM)-12.24M NOK
Revenue/Share0.0010 NOK
Last Price3.500 NOK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010714785
Valuation
P/E (Trailing)—
P/E (Forward)-10.16
PEG—
EV/EBITDA-46.19
EV/Revenue2231.07
P/S1841.23
P/B1.59
EPS (TTM)-0.46
EPS (Forward)-0.31
52W Range
1.44077% of range4.100
52W High4.100 NOK
52W Low1.440 NOK
Profitability
Gross Margin100.00%
Oper. Margin-2723.33%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-13.37%
ROA-12.25%
Growth
Revenue Growth75.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.46M NOK
CapEx (TTM)38.00K NOK
FCF Margin-3400.38%
FCF Yield-1.65%
Net Debt-48.95M NOK
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity0.03
Current Ratio12.66
Quick Ratio12.66
Book Value/Sh1.978 NOK
Cash/Share0.1250 NOK
Dividends
Fwd Div Rate1.000 NOK
Trail. Div Rate0.0000 NOK
Div. Yield29.76%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 27, 2025
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.500 NOK
Target Range4.500 NOK – 4.500 NOK
# Analysts1
Ownership
Shares Out.326.55M
Float213.59M
Insiders43.60%
Institutions17.83%
Technical
SMA 503.175 (+10.2%)
SMA 2002.573 (+36.0%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)1.01M
Avg Vol (10d)972.83K
Technical Indicators
RSI (14)48.2
MACD-0.0058
MACD Signal-0.0005
MACD Hist.-0.0053
BB Upper3.323 NOK
BB Middle3.163 NOK
BB Lower3.003 NOK
BB Width10.12%
ATR (14)0.1624 NOK
Vol Ratio (20d)5.15x